Cancer stem cell biomarkers SOX2 and Oct4 in cervical cancer patients undergoing chemoradiotherapy
Asia-Pacific Journal of Clinical Oncology · 2024
DOI: 10.1111/ajco.14049 ↗Kurz gefasst
Fachartikel in der Zeitschrift Asia-Pacific Journal of Clinical Oncology, 2024. Verfasst von Deep Chakrabarti und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiotherapy, King George's Medical University, Lucknow, India. Hauptthemen laut MEDLINE: Octamer Transcription Factor-3, SOXB1 Transcription Factors, Uterine Cervical Neoplasms, Biomarkers, Tumor. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 42 Literaturangaben. Gefördert von: King George's Medical University.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
Cancer stem cell biomarkers SRY (sex‐determining region Y)‐box 2 (SOX2) and octamer‐binding transcription factor 4 (Oct4) account for radioresistance in cervical squamous cell cancers (CSCCs). Their clinical implications are limited and contradictory.
Methods
In this prospective cohort study, we recruited patients with FIGO IB2‐IVA CSCC treated with primary chemoradiotherapy on regular follow‐up. Tissue biopsy specimens were evaluated for SOX2 and Oct4 expression by immunohistochemistry, quantified by a product of proportion and intensity scores.
Results
A total of 59 patients were included. Most had a moderately differentiated (81%), keratinizing (59%) CSCC, and ≥FIGO stage IIB disease (95%). SOX2 expression (high:low 21:38 patients) and Oct4 expression (high:low 4:55 patients) had a significant interrelation ( p = 0.005, odds ratio (95% CI) − 1.23 (1.004–1.520)). At a median follow‐up of 36 months, the 3‐year overall survival (OS) was 60% and 53% for low and high SOX2 expression ( p = 0.856), and 54% and 100% for low and high Oct4 expression ( p = 0.114). The 3‐year disease‐frese survival (DFS) was 65% and 50% in the low and high SOX2 expression ( p = 0.259), and 59% and 75% for low and high Oct4 expression ( p = 0.598). SOX2 expression was the only variable significantly associated with a lower OS and DFS on regression analysis.
Conclusion
Our study demonstrated a trend toward improved OS and DFS with low SOX2 and high Oct4 expression in CSCC patients undergoing chemoradiotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiotherapy, King George's Medical University, Lucknow, India.
- The Royal Marsden NHS Foundation Trust, Sutton, UK.
- Department of Pathology, King George's Medical University, Lucknow, India.
- Department of Radiation Oncology, Super Speciality Cancer Institute & Hospital, Lucknow, India.
- Laboratory Medicine, Medanta Hospital, Lucknow, India.
- Department of Surgical Oncology, King George's Medical University, Lucknow, India.
ORCID-Profile: Deep Chakrabarti, Shiv Rajan
Förderung
- King George's Medical University
Zitieren
APA
Chakrabarti, D., Qayoom, S., Srivastava, K., Resu, A. V., Kukreja, D., Goel, M. M., Singh, U. S., Akhtar, N., Rajan, S., Verma, M., Gupta, R., & Bhatt, M. L. B. (2024). Cancer stem cell biomarkers SOX2 and Oct4 in cervical cancer patients undergoing chemoradiotherapy. Asia-Pacific Journal of Clinical Oncology. https://doi.org/10.1111/ajco.14049
Vancouver
Chakrabarti D, Qayoom S, Srivastava K, Resu AV, Kukreja D, Goel MM, et al. Cancer stem cell biomarkers SOX2 and Oct4 in cervical cancer patients undergoing chemoradiotherapy. Asia-Pacific Journal of Clinical Oncology. 2024. doi:10.1111/ajco.14049
BibTeX
@article{Chakrabarti2024,
author = {Chakrabarti, Deep and Qayoom, Sumaira and Srivastava, Kirti and Resu, Abigail Veravolu and Kukreja, Divya and Goel, Madhu Mati and Singh, U S and Akhtar, Naseem and Rajan, Shiv and Verma, Mranalini and Gupta, Rajeev and Bhatt, Madan Lal Brahma},
title = {Cancer stem cell biomarkers SOX2 and Oct4 in cervical cancer patients undergoing chemoradiotherapy},
journal = {Asia-Pacific Journal of Clinical Oncology},
year = {2024},
doi = {10.1111/ajco.14049}
}
EUVIMED